Results 141 to 150 of about 280,719 (209)

BATAILLE ON MIMETIC HETEROLOGY

openaire   +2 more sources

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Nature Medicine, 2022
The recent emergence of the SARS-CoV-2 Omicron variant is raising concerns because of its increased transmissibility and its numerous spike mutations, which have the potential to evade neutralizing antibodies elicited by COVID-19 vaccines.
Carolina Lucas, Valter Vinicius Silva Monteiro, Chantal B F Vogels   +2 more
exaly   +2 more sources

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Nature Medicine, 2021
Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available.
Tina Schmidt, David Schub, Janine Mihm
exaly   +2 more sources

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Lancet, The, 2022
Summary Introduction The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has been widely used in a two-dose schedule. We assessed whether a third dose of the homologous or a different vaccine could boost immune responses. Methods RHH-001
Lily Yin Weckx, Wanwisa Dejnirattisai, Juthathip Mongkolsapaya   +2 more
exaly   +2 more sources

Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination

Nature, 2021
Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine1,2, European health authorities recommended that patients under the age of 55 years who received one dose of ChAdOx1-S-nCoV-19 receive a second dose of the Pfizer BNT162b2 ...
Bruno Pozzetto, Vincent Legros, Sophia Djebali   +2 more
exaly   +2 more sources

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Lancet Respiratory Medicine,the, 2021
Background Heterologous vaccine regimens have been widely discussed as a way to mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 vaccines. We aimed to assess the reactogenicity and immunogenicity of heterologous
David Hillus, Tatjana Schwarz, Pinkus Tober-Lau   +2 more
exaly   +2 more sources

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Lancet, The, 2021
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca;
Sue Charlton, Andrea M Collins, Saul N Faust   +2 more
exaly   +2 more sources

Homologous and Heterologous Covid-19 Booster Vaccinations

New England Journal of Medicine, 2022
BACKGROUND: Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring.
Robert L Atmar, Kirsten E Lyke, Meagan Bolles   +2 more
exaly   +2 more sources